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Introduction  
INTRODUCTION 
Hepatocellular carcinoma is one of the commonest malignancies 
that account to about half a million deaths yearly. It ranks in the fifth 
place globally. 80% of these cases are seen in the Asian- Pacific region. 
Less than 20% of hepatocellular carcinomas get the appropriate treatment 
as surgical resection as therapy when they are diagnosed. It is purely due 
to the advanced stage of the disease at the time of diagnosis. 
             The risk factors of this cancer are well defined. Worldwide, about 
80% of cases are due to cirrhotic livers. In Asia and Africa it is hepatitis 
B virus infection; as it is an oncogenic virus, it can cause cancer in the 
absence of cirrhosis. 
In countries like Europe, Japan and United States, the bulk of the 
infection is due to hepatitis C than B because of the vaccination given for 
newborns. 
Immunohistochemistry may help distinguishing hepatocellular 
carcinoma and its mimics. The challenges are attributed as follows: 
1) Hepatic stem cell lineage can give rise to any neoplasm. 
2) Nodular lesions of liver. 
3) Metastatic tumours of liver. 
4) Serum Alpha Fetoprotein has its own limitations. 
The pivotal role of immunohistochemistry is in differentiating 
benign nodular lesions from reactive conditions, benign nodular lesions 
from well differentiated hepatocellular carcinoma, cholangiocarcinoma 
from metastasis and poorly differentiated tumours of hepatic origin and to 
ascertain the origin of the tumour whether primary or secondary. 
           Alpha Fetoprotein is the protein that determines the histogenesis of 
the tumour from the liver. 
Bile canaliculi are stained by p-CEA and CD10. 
Hep Par 1 is a hepatocyte marker. 
CAM 5.2, Cytokeratin 8 and Cytokeratin 18 stain mature 
hepatocytes and nodules. 
Cytokeratin 7, Cytokeratin 19, Cytokeratin 20 and Cytokeratin 
AE1/AE3 are absent. 
Sinusoids take up CD34. 
Alpha Fetoprotein, p-CEA, CD10 and CD34 are the primary panel 
markers to tell that the malignant nodule is hepatocyte in origin. 
If histogenesis is questioned, then Hep Par 1 and Cytokeratin come 
into play. 
The  purpose  of  this  study  is  to  examine  the  usefulness  of  
immunohistochemistry  in  differentiating  primary  from  metastatic  
neoplasms  of  liver  and  to  evaluate  the  role  of  reticulin  stain  to  
differentiate  benign  from  malignant  lesions  of  liver. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim of the Study  
AIM OF THE STUDY 
1) To  study  the  role  of  immunohistochemistry  in  differentiating  
primary  from  metastatic neoplasms  of  liver. 
2) To  evaluate  the  usefulness  of  reticulin  in  differentiating  
benign  from  malignant lesions of  liver. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of Literature 
  
REVIEW OF LITERATURE 
Hepatocellular carcinoma is a primary malignant tumour arising in 
liver, leading to mortality within a year. It commonly arises in a cirrhotic 
liver after a primary insult 20 to 30 years ago. But exceptions are noted 
where 25% of patients have no previous history or risk factors leading to 
cirrhosis. 
After the introduction of vaccination for hepatitis B infection, 
screening and treatment for virus C infection decrease in hepatic lesions 
due to alcohol, cancer death due to hepatocellular carcinoma has gone 
down.  
As the latency period from the damage caused to hepatocytes to the 
development of hepatocellular carcinoma is very prolonged, it takes years 
for the incidence of hepatocellular carcinoma to decrease after the usage 
of these interventions
1
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EPIDEMIOLOGY 
Hepatocellular carcinoma accounts for 2% of all malignancies; 
since 1980s, the incidence has increased. There is increase in two fold in 
age adjusted incidence rate before one decade.  
Annually there are 560,000 new cases diagnosed. It is the eighth 
most common cancer occurring in women. The prevalence of hepatitis B 
and C infections is directly proportional to the incidence of hepatocellular 
carcinoma. 
In Asia and Africa, there is a high incidence of hepatocellular 
carcinoma as 120 cases per 100,000 population
1
. These high rates are due 
to infectious hepatitis. 
RACE 
Asians are the most common victims of hepatocellular carcinoma 
probably due to childhood infections with hepatitis B. As a result of 
implementation of vaccination for hepatitis B in many Asian countries, 
there is a fall in number of cases of primary liver malignancies. 
SEX 
Hepatocellular carcinoma is more common in men than in women. 
 
 
AGE 
Hepatocellular carcinoma peaks in the fourth and fifth decade of 
life. If the younger age group is affected, hepatitis infection with B and C 
is related to the occurrence of this cancer. 
MORTALITY/MORBIDITY 
          The survival rate of the patient from the time when the cancer is 
diagnosed is 6 to 8 months. The extent of cirrhosis damaging the liver is 
directly proportional to the survival period of the patient. Most common 
factors causing cirrhosis are 
1) Alcohol ingestion 
2) Hepatitis B or C infection 
3) Autoimmune diseases of liver 
4) Iron overload in the body (Hemochromatosis) 
  Liver is a common site for both primary and secondary tumours. 
25% of metastatic tumours from various solid organs involve the liver. 
    The secondary tumours are most commonly adenocarcinomas 
followed by squamous cell carcinoma and neuroendocrine tumours. 
Melanomas, lymphomas and rarely sarcomas metastasize to the liver. 
Presentation of secondary tumours are usually as multiple 
umblicated nodules on the surface of the liver rather than solitary lesions. 
However, histopathological diagnosis is necessary to confirm the lesion.   
The image-guiding sampling techniques using fine needle 
aspiration (FNA) or needle core biopsy(NCB) techniques are the best for 
diagnosing liver lesion. The key to diagnosis is proper sampling of the 
lesion.  
The important role of a pathologist is to determine the type of the 
tumour, to differentiate primary from secondary malignancy and in case 
of secondary tumour, to assess the possible site of origin. After an initial 
diagnosis of the lesion by routine histopathlogical examination, various 
immunohistochemical markers may be used for accurate diagnosis of the 
tumour.  
SAMPLING TECHNIQUE AND PREPARATION 
Tissue diagnosis is important to start the treatment regime for the 
patient. The most frequently used modalities to obtain the tissue are Fine 
Needle Aspiration (FNA) and Needle Core Biopsies (NCB) which may 
be ultrasound or CT guided. 90% of specimens are obtained in these 
techniques fetch a good histopathology report. The usage of these both 
techniques are decided based on the site where the mass is located, the 
size and the consequences of the complications
5
. 
            Liver happens to be the frequent site of metastatic disease due to 
its blood supply.  
 Sampling of the representative area is very important for the final 
diagnosis. Clinical history of the patient is of great value to the 
pathologist.  
 Radiological findings, serum markers and any past history of 
neoplastic lesion is pertinent
6
. 
PROCEDURE OF LIVER BIOPSY 
            The first liver aspirate was performed by the German physician 
Paul Ehrlich in 1983. 
  Percutaneous liver biopsy was first reported in the 1920s. The 
transjugular approach was pioneered by radiologist Charles Dotter in the 
1970s. 
             Before performing liver biopsy, all laboratory investigations 
including liver function tests, platelet count and coagulation studies are 
done. 
ADEQUACY OF LIVER BIOPSY 
According to a study by Atif Zaman et al in 2011, liver biopsy 
specimen which measures 15 mm in length and 2 mm in diameter and 
which is composed of atleast 6 portal tracts is said to be adequate. This 
accounts to about  1/50,000
th
 of the volume of an adult liver. 
           Few pathologists consider 4 cm of biopsy sample to be adequate; 
whereas other few consider 1 cm to be enough to reduce the variations 
among the observers.  
Finally, the exact size of the liver biopsy samples to be received for 
accurate evaluation still remains inconclusive. 
INDICATIONS OF LIVER BIOPSY 
1) Evaluation of abnormal laboratory tests 
2) Suspected hepatic neoplasms 
3) Grading and staging of chronic hepatitis 
4) Evidence of granulomatous disease 
5) Liver transplantation to evaluate rejection 
CONTRAINDICATIONS OF LIVER BIOPSY PROCEDURE 
1) Increased prothrombin time 
2) Thrombocytopenia 
3) Ascites  
4) Suspected hemangiomas 
5) Suspected echinococcal infection 
6) Un co-operative patient 
EQUIPMENT 
 TYPES OF BIOPSY NEEDLES: 
        CUTTING NEEDLES: Vim-Silverman 
        SUCTION NEEDLES: Meghini, Klatskin, Jamshidi 
PROCEDURE 
           Patient is placed in a supine position and pillows are removed. He 
is asked to raise the right arm behind the head, and legs and feet angled to 
the left. Percussion is done to get the maximum dullness and this site is 
marked marked with a pen.  
           Now, local anaesthesia is used and a small incision is made on the 
skin. Under image guidance (USG or CT), liver biopsy needle is inserted 
and biopsies are taken. 
COMPLICATIONS 
1) Pain 
2) Hemorrhage 
3) Bile peritonitis 
4) Bacteremia 
5) Sepsis 
6) Hemothorax 
7) Pneumothorax 
8) Accidental puncture of other organs 
              Many histochemical stains are used to demonstrate the 
architecture of hepatic parenchyma and for screening of metabolic 
diseases. These metabolic diseases include haemochromatosis, alpha-1-
antitrypsin deficiency and wilson’s disease. Depending on the case 
studied, these stains are used. 
               The most commonly used stains, apart from haematoxylin and 
eosin, are reticulin, collagen stain (van Gieson), PAS stain, stain for 
copper binding protein like orcein and for iron, Perl’s stain. Other special 
stains which can be used are rhodanine, rubeanic acid, acid fast bacilli 
and amyloid stains. 
              If no tumour tissue is found in the initial routine haematoxylin 
and eosin stained section, deeper sections are necessary before giving a 
negative report. The difficulty arises when there is a well differentiated 
hepatocellular lesion e.g. well differentiated hepatocellular carcinoma, 
focal nodular hyperplasia, liver cell adenoma, etc. If additional sections 
also reveal no lesional tissue, further biopsies and/or investigations are 
required for diagnosis.  
 
 
 
PROCESSING OF THE SPECIMEN 
 The needle biopsy specimen is gently placed into a fixative as soon 
as it is received. The tissue must be handled with great care and excessive 
manipulation of the specimen should be avoided.  
Frozen sections may be necessary to demonstrate lipids. Formal 
saline and buffered formalin are good routine fixatives. 
HEPATOCELLULAR CARCINOMA 
SMALL HEPATOCELLULAR CARCINOMA 
MACROSCOPIC FEATURES 
Small hepatocellular carcinomas are tumours less than 2 cm in 
diameter. 
 It is difficult to distinguish from a macro-regenerative nodule on 
gross inspection.They are vaguely nodular with ill defined borders and 
difficult to distinguish from the surrounding cirrhotic liver. 
MICROSCOPIC FEATURES 
Small hepatocellular carcinomas are well-differentiated, consisting 
of thin, irregular trabeculae of crowded hepatocytes. 
 Mallory hyaline is seen. Reticulin stain shows loss of reticulin 
fibres. It is distinguished from high-grade dysplastic nodule by increase 
in nuclear density twice normal but definite nuclear atypia. 
ADVANCED HEPATOCELLULAR CARCINOMA 
MACROSCOPIC FEATURES 
The gross appearance of advanced hepatocellular carcinoma 
depends on the presence or absence of cirrhosis and the size of the 
tumour. Tumours arising in a noncirrhotic liver usually are large masses.  
They may present with satellite nodules; whereas those associated 
with cirrhosis present as multiple discrete nodules which cannot be 
differentiated from cirrhosis. 
The liver is large and expanded by one or more tumour nodules. 
They are green bile-stained and have pale yellow and white areas. They 
contain foci of necrosis and hemorrhage. 
Blood vessel invasion is common if the tumour is large. Tumour 
nodules at multiple sites are either due to synchronous primaries 
(multicentric growth) or due to intrahepatic metastasis from the tumour 
which would have spread through portal vein branches. 
MICROSCOPIC FEATURES 
Hepatocellular carcinomas which are well differentiated resemble 
normal liver. Carcinomas of liver were first classified by Edmonson and 
Steiner who devised a four-tired system based on autopsy studies. This 
classification was then modified by AFIP and other systems. 
Subsequently World Health Organisation devised a system which divides 
hepatocellular carcinomas into well differentiated, moderately 
differentiaied and poorly differentiated carcinomas.  
Bile located within the neoplastic cells or tubular lumina is 
characteristic of hepatocellular carcinoma.   
Differentiation of the tumour depends on the nuclear grading 
according to the World Health Organisation classification. Stroma is 
deficit in hepatocellular carcinoma. Exceptions are fibrolamellar 
carcinoma and scirrhous carcinoma. 
Tumours with high nuclear grading are associated with poor 
survival rate and show positivity in positron emission tomography (PET) 
imaging. 
Edmonson and Steiner devised a four-tired system based on 
autopsy data. This was subsequently modified in a large series reported 
from the AFIP and other similar systems have been proposed. The World 
Health Organization Classification divides tumours into well, moderately 
and poorly differentiated grades. Most tumours are moderately 
differentiated and more than one histological grade is often present within 
a tumour. 
Although tumour grade has not universally been shown to have a 
significant impact on outcome, higher nuclear grade has been reported to 
predict poorer survival in hepatocellular carcinomas resected with 
curative intent and higher tumour grade corresponds to positivity on 
positron emission tomography (PET) imaging. 
HISTOLOGICAL PATTERNS 
Multiple histological patterns are observed. These patterns are not 
important to assess the prognosis except in case of fibrolamellar variant; 
but recognizing these different patterns are useful so that they are not 
misdiagnosed as metastatic carcinomatous deposits involving the liver. 
These patterns are as follows: 
TRABECULAR  
              This is a commonly found pattern which resembles normal 
hepatic architecture.The tumour cells grow in cords or plates separated by 
vascular channels lined by endothelial cells and kupffer cells, with little 
intervening stroma. The trabeculae vary in thickness, from only a few 
cells thick to broad structures 20 or so thick. The reticulin framework is 
reduced or absent. 
 
 
 
COMPACT 
            Its occurrence varies from 5 to 15%. Confluent growth results in a 
solid growth pattern, with inconspicuous or obliterated sinusoids. 
PSEUDOGLANDULAR (ACINAR) 
             This pattern is important to recognize because it is often mistaken 
for metastatic adenocarcinoma, cholangiocarcinoma or hepatocellular 
carcinoma combined with cholangiocarcinoma. The tumour is composed 
of spaces which are not true glands; they represent dilated bile canaliculi  
lined by a single layer of tumour cells. These pseudoglands appear to be 
freely floating and no fibrous stroma is seen in the background. This 
feature helps to distinguish from adenocarcinomatous deposits in the 
liver.  
  These spaces between the tumour cells sometimes have acellular 
eosinophilic material which may show positivity for PAS but it is 
negative for mucicarmine and alcian blue. 
The following categories are recognized cytological variants of 
hepatocellular carcinoma: 
PLEOMORPHIC (GIANT CELL) 
          This variant contains tumour cells which show marked variation in 
size and shape. Bizzare cells are also noted. The trabecular pattern often 
seen in well differentaiated hepatocellular carcinoma is often lacking in 
this variant.  
There is loss of cohesion of tumour cells which indicates that this 
is a high grade variant of hepatocellular carcinoma. In these cases  
extensive sectioning is mandatory  to find any focus of typical 
hepatocellular carcinoma. 
CLEAR CELL 
              This type of hepatocellular carcinoma is called so because it 
contains tumour cells with abundant clear cytoplasm due to glycogen                 
and / or fat. This variant has to be differentiated from other neoplasms 
with clear cytoplasm like metastatic renal, adrenal and ovarian 
carcinomas. Additional sections have to be taken to find evidence of 
typical hepatocellular carcinoma. In these instances serum AFP level, 
presence of chronic liver disease and the absence of extra-hepatic mass 
may lead one to correct diagnosis of hepatic primary neoplasm. 
SARCOMATOID (SPINDLE CELL, PEUDOSARCOMATOUS)  
This accounts for about 4% of hepatocellular carcinomas. Areas 
with spindle shaped cells with nuclear atypia constitute the sarcomatoid 
foci. There may be both carcinomatoid and sarcomatoid foci in the same 
tumour. Areas resembling fibrosarcoma or malignant fibrous 
histiocytoma may be seen. Hence, extensive sampling is needed to 
demonstrate the primary nature of the tumour.  
FIBROLAMELLAR HEPATOCELLULAR CARCINOMA 
This variant justifies its separation from other types of 
hepatocellular carcinoma because of is distinct clinical and pathological 
features and natural history. The patients are younger than those with 
other types of hepatocellular carcinoma. Its incidence is equal in men and 
women. 
The fibrolamellar variant is not associated with chronic liver 
disease, cirrhosis or any other known risk factor. 
Grossly, the tumours are hard unlike other hepatocellular 
carcinomas, due to the presence of fibrous stroma. Central scarring may 
be seen in the tumour. 
Microscopically, the tumour is composed of distinctive cytological 
features with a fibrous stroma. The stroma is thick and contains 
hyalinised collagen bundles. These bundles of collagen are arranged in 
parallel lamellae of varying thickness, so the name fibrolamellar.  
The cells are large and polyhedral. They have a dense eosinophilic 
cytoplasm due to abundant mitochondria. Approximately half of the 
tumours have ground glass cytoplasmic inclusion bodies called ‘pale 
bodies’. Bile may be seen within the tumour cells. Mitotic activity is low. 
These tumours are slow growing and are often surgically 
resectable; hence, they carry a better prognosis compared to other types 
of hepatocellular carcinoma. 
ROLE OF RADIOGRAPHY IN THE DIAGNOSIS OF HEPATIC 
MALIGNANCIES  
Radiography i.e. CT or MRI scan is usually performed in case of 
mass lesions of liver. CT scan shows increase in vascularity, 
calcifications and fat within the lesion.           
CT and MRI imaging can assess  
1) whether the tumour is single or multiple  
2) size of the tumour 
3) whether the tumour is well defined or ill defined. 
The treatment of hepatocellular carcinoma depends on the 
1) the size of the tumour 
2) stage at which the tumour is diagnosed 
3) vascular and capsular invasion 
4) presence or absence of metastatic disease 
5) whether the tumour is hypervascular or hypovascular. 
Radiographically, most metastatic adenocarcinomas of liver show 
decrease in vasularity. 
 
PROGNOSIS OF HEPATOCELLULAR CARCINOMA  
The survival rate of the patients with hepatocellular carcinoma is 
generally worse. Most patients die within a year. The reasons for such 
poor prognosis are the large tumours which present late and insufficient 
medical facilities for proper diagnosis and treatment especially in the 
developing countries.         
The prognosis of patients with metastatic disease is generally poor; 
and the treatment options include reception, cryoablative therapy and 
ethanol injection. All these modalities give a palliative cure in the 
management of those patients with metastatic disease involving the liver. 
PRECURSORS OF HEPATOCELLULAR CARCINOMA 
These include hepatocellular changes and nodular lesions. These 
lesions are important to identify because they need patient surveillance 
and if necessary surgical treatment. 
 
They are as follows: 
Liver cell dysplasia: 
a) Small cell type 
b) Large cell type 
Large-cell liver cell dysplasia (large cell change) 
Large cell type of liver cell dysplasia is common. It shows nuclear 
enlargement, pleomorphism, multinucleation and multiple nucleoli. It is 
seen in hepatitis B virus infection, cirrhosis and hepatocellular carcinoma. 
They also show aneuploidy. It is strongly due to cholestasis or normal 
cell-polypoidisation. The large cell dysplasia is an important independent 
risk factor for hepatocellular carcinoma. 
Small-cell liver cell dysplasia (small cell change) 
This shows enlarged and hyperchromatic nucei arranged in 
clusters. There is high cell proliferation rate and may lead to 
hepatocellular carcinoma. 
Other cellular changes indicated in pre-malignant conditions 
include intracytoplasmic Mallory bodies, areas of regeneration which 
show glycogenesis and oncocytic change in hepatocytes or bulging 
nodularity, siderotic macroregenerative nodules which show iron negative 
foci and  livers of patients with hereditary haemochromatosis which have 
iron free foci.  
The dysplasia may be further categorised into  
i. Low grade dysplasia and 
ii. High grade dysplasia 
When clusters of large-cell or small-cell dysplastic hepatocytes less 
than 1 mm are seen, they are called as dysplastic foci. 
MACROREGENERATIVE NODULE 
This refers to a regenerative nodule larger than 8 mm; it develops 
more commonly in cirrhotic liver. The livers with macroregenerative 
nodules may also have associated hepatocellular carcinoma. 
The macroregenerative nodule under microscopy shows 
hyperplastic hepatocytes in plates of two or three cells thick. There is no 
cellular atypia seen. The portal tracts and fibrous septa containing bile 
ducts, hepatic arteries and portal vein branches are seen within the 
nodule. Fatty change, biliary plugging and Mallory bodies are often 
noted.   
DYSPLASTIC NODULE 
            The dysplastic nodules do not show features of macroregenerative 
nodule both cytologically and architecturally. They show changes of large 
and small-cell liver cell dysplasia. The cells are large and small with 
increased cellularity, loss of cohesiveness. Reticulin is also absent within 
the nodule.  
The macroregenerative nodules and the dysplastic nodules should 
be differentiated from hepatocellular carcinoma. Features for carcinoma 
are increased nuclear cytoplasmic ratio, dysplastic cells, fatty change 
increased mitosis, broad trabeculae, infiltrative margins and absence of 
reticulin.    
BENIGN AND BORDERLINE HEPATOCELLULAR TUMOURS 
1) Hepatocellular adenoma 
2) Focal nodular hyperplasia and 
3) Nodular regenerative hyperplasia 
are the three notable lesions of liver which are entirely benign. These 
lesions are to be differentiated from the lesions which are considered as 
the potential precursors of hepatocellular carcinoma. 
The above three proliferations originate in the normal liver; 
whereas the precursors more commonly arise in a cirrhotic liver. 
HEPATOCELLULAR ADENOMA 
        It is a benign tumour of liver which arises in a non-cirrhotic 
background. It is more common in middle aged women who take oral 
contraceptive pills and in men who take anabolic steroids. 
      Clinically it can be differentiated from hepatocellular carcinoma by 
the serum level of   Alpha Feto-protein which is within normal limits in 
case of hepatocellular adenoma. 
GROSS 
             The tumour is usually solitary and it is well delineated from the 
surrounding normal liver. The colour of the tumour is generally grey 
yellow. But areas of necrosis and hemorrhage may be seen within the 
tumour. 
MICROSCOPY 
         The hepatocellular adenoma may be confused with normal liver 
when viewed with a low power. But on careful observation it may be 
noted that unlike normal hepatic parenchyma, no portal tracts or biliary 
ducts are made out within the tumour. Instead arteries and veins which 
are randomly distributed are seen. This is an important feature of this 
lesion. 
           The individual cells may show fatty change. Focal nuclear atypia 
is sometimes seen but mitosis is absent. 
            The tumour in most cases is entirely benign. But it is observed 
that a category of the tumour caused by mutation in beta-catenin gene has 
a propensity to develop hepatocellular carcinoma.  
             The differential diagnosis includes well-differentiated 
hepatocellular carcinoma. The differentiating features include significant 
nuclear pleomorphism and prominent nucleolus. Another important clue 
to diagnosis is that reticulin is lost in hepatocellular carcinoma and is 
retained in hepatocellular adenoma. 
The prognosis of hepatocellular adenoma is good, many cases 
having a tendency to regress when the hormonal drugs are withdrawn. 
      Surgical excision is generally curative. But surveillance is needed 
if hormones are not known to be the risk factors, the tumour shows 
nuclear pleomorphism or when the tumour is not resected completely. 
 
 
FOCAL NODULAR HYPERPLASIA 
          This lesion is also a benign proliferation of hepatocytes. Unlike the 
hepatocellular adenoma which is more common in women, the incidence 
of focal nodular hyperplasia is equal in both sexes. 
      The exact etiology of focal nodular hyperplasia is not clear; but it 
is observed that this is a localized proliferation of benign hepatocytes 
which is seen around an anomalous vessel. Focal nodular hyperplasia like 
lesions can develop in a liver with cirrhosis and so this lesion is important 
to be recognized because of its prognostic significance. 
GROSS 
            The lesion usually presents as a single mass beneath the capsule. 
Cut surface is usually grey white to tan in colour. A central radiating scar 
is seen in many cases especially if the mass is less than 10 mm in size. 
HISTOLOGY 
              Focal nodular hyperplasia, as the name indicates, is composed of 
non-neoplastic hepatocytes arranged in nodules separated by thick fibrous 
septa. Bile ducts, few branches of arteries and inflammatory infiltrate are 
seen within the septa. Similar to hepatocellular adenoma, portal tracts and 
bile ducts are absent within this nodule. 
              These lesions have entirely benign course and need no resection 
unless symptomatic. 
NODULAR REGENERATIVE HYPERPLASIA 
      This is less common lesion when compared to focal nodular 
hyperplasia and hepatocellular adenoma. It is important to diagnose the 
lesion because of its close resemblance to cirrhosis grossly; and the 
prognosis varies between the two conditions. Nodular regenerative 
hyperplasia involves the liver in a diffuse manner. 
GROSS 
       The cut surface of the liver with nodular regenerative hyperplasia 
shows multiple tan coloured nodules which diffusely involve the liver 
which closely resembles cirrhosis. 
MICROSCOPY 
    The characteristic histopathological picture is hyperplastic nodules 
of benign hepatocytes separated by atrophic hepatocytes without 
significant fibrosis; this differentiates it from cirrhosis. Congestion of 
sinusoids and compression of central veins are seen. The hepatocytes 
which are found resemble normal hepatocytes and those seen between the 
nodules are small and atrophic. 
This pattern of alternative regenerating and the atrophic 
hepatocytes is demonstrated by reticulin stain. 
Differential diagnosis includes cirrhosis of liver. This difficulty can 
be overcome with the help of special stains like trichrome and reticulin 
stains. 
RETICULIN  
Reticulin is used to describe a type of fibre which is seen in the 
connective tissue. It is made of type 3 collagen
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. Reticulin fibres cross 
link to form a fine meshwork (reticulin). This reticulin network acts as a 
supporting mesh in various soft tissues like liver, bone marrow, and the 
tissues and organs of lymphatic system. 
The Bielschowkys’ technique of reticulin staining by silver 
impregnation was found by Maresch in 1905.   
Since the 1920s, the studies on “reticulin” distribution were based 
entirely on silver impregnation technique. Gomori’s and Wilder’s 
methods to stain reticulin fibres in the cells of various organs revealed 
different staining patterns. 
STRUCTURE 
The fibres of reticulin are made up of various types of type 3 
collagen which are very thin and delicate strands. Thus, the collagen 
strands yield an orderly network for a good support to the tissues. These 
strands of collagen are seen connected to carbohydrate moiety. Hence, 
they stain both reticulin and carbohydrate stains but cannot be seen in 
routine hematoxylin and eosin stained sections. Since they have affinity 
for silver salts, these fibres are termed argyrophilic. 
PRINCIPLES OF RETICULIN STAINING 
Stains used for reticulin, as already mentioned are silver stains 
which are depend on the argyrophilia of the reticular fibres. There are two 
commonly used reticulin stains; these are the Gomori’s stain and the 
Gordon and Sweet’s stain. 
UTILITY OF RETICULIN 
 The fine network of reticular fibres are especially seen in the 
hepatic parenchyma at the site of trabeculae. This network of reticulin 
gives good connective tissue support to the liver. The basis of this 
information gives valuable knowledge regarding the morphology of 
hepatic parenchyma. 
If necrosis occurs in hepatocellular parenchyma due to some 
damage, the reticulin fibres surrounding the hepatocytes are collapsed 
leaving a space behind. So, when reticulin fibres are seen crowded, it 
indicates focal hepatocyte loss.  
If regeneration of cells of liver hepatocytes occurs, these fibres of 
reticulin reveal increase in thickness of liver cell plates of more than   
one-cell.  
In a study by Norredam K in 1979, among 7763 autopsies 
performed, there were 309 cases of cirrhosis of the liver and 52 cases of 
carcinomas of liver. Of the latter, 45 were hepatocellular carcinomas, 4 
combined hepatocellular carcinoma and cholangiocarcinoma and 3 
cholangiocarcinoma. The reticulin stain was found very valuable in 
hepatocellular carcinoma both for descriptive and diagnostic purposes. 
According to a study by Bergman and Graeme in 1997
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, the stain 
pattern was analyzed using semi-quantitative system: normal, variable, 
decreased and absent based on whether the cells of hepatic parenchyma 
are than or less than three-cells thick. 
About 90% of cases of benign hepatic lesions showed normal 
network of reticular fibres i.e. took the stain along the trabeculae which 
are not more than three cell thick. There seemed to be great reduction in a 
specimen of fatty liver and it was totally absent in a biopsy specimen of 
cirrhotic liver. On the other hand, every case of hepatocellular carcinoma 
showed a totally absent , reduced or variable pattern of reticulin staining, 
revealing an increase in thickness.  
METASTATIC CARCINOMATOUS DEPOSITS 
ADENOCARCINOMAS 
Adenocarcinomas are the most common carcinomas to metastasize 
to the liver. In order of frequency are pulmonary, colonic, pancreatic and 
gastric malignancies accounting for approximately 25%, 16%, 11% and 
6% of the cases respectively. Other carcinomas like ovarian, uterine, 
prostatic and biliary carcinomas represent 4% each. 
           Adenocarcinomas represent those tumours which arise in a 
glandular tissue. The most common morphology is glandular pattern lined 
by tall columnar cells, which is similar to the glands seen in the native 
organ.  
The adenocarcinoma shows focal mucin production, and forms 
signet ring cells and acinar pattern. Mucin can be demonstrated with a 
histochemical stain like mucicarmine.  
 The exact site of primary is difficult to assess with the help of 
morphological characteristics alone; but still some primary sites can be 
suspected which helps in the diagnosis in needle core biopsies. The 
tumours which fall in this category are those from colon, breast, 
pancreaticobiliary tract,etc... 
Colorectal carcinoma shows a central dirty necrosis in the glands. 
Ductal adenocarcinoma of breast reveals a monomorphic population. 
Lobular carcinoma is seen with cells infiltrating in single file pattern. The 
cells with a targetoid cytoplasmic lumen are helpful in the diagnosis of 
mammary carcinomas.  
Pancreaticobiliary carcinomas do not have a specific pattern but 
may be suspected when they show abundant cytoplasmic mucin or clear 
nuclei. However, a good clinical history is needed to differentiate primary 
cholangiocarcinoma from metastatic pancreaticobiliary carcinoma. 
The morphological characteristics of other various carcinomas like 
pulmonary, uterine, esophageal carcinomas and in the stomach donot 
have their specific findings for their diagnosis in the biopsies. 
SQUAMOUS CELL CARCINOMA 
Squamous cell carcinoma is a rare metastatic tumour to the liver. 
The carcinomas which should be kept on mind when dealing with the 
origin are pulmonary and esophageal tumours, and carcinomas from head 
and neck, gonads and anorectum. The individual cells reveal 
keratinisation as an evidence for the diagnosis; however this is not always 
mandatory. 
            Immunohistochemistry is also not useful. Only detailed history 
regarding the patient’s clinical status may be helpful in identifying the 
primary site. 
NEUROENDOCRINE CARCINOMA                     
Neuroendocrine carcinomas have various degrees of 
differentiation. The cells of benign tumours like carcinoids appear 
monotonous showing minimal mitosis. The distinct salt and pepper 
pattern of chromatin is seen in these cells. 
Carcinoids arise anywhere in the gastrointestinal tract. Highly 
malignant tumours like small cell carcinoma arising in the lung are 
common. They reveal moulding of nuclei high mitotic rate, areas of 
necrosis and crush artifacts as seen in the primary lung carcinoma. 
Immunohistochemical studies are useful in confirming the 
diagnosis of neuroendocrine tumours. The markers used in the diagnosis 
are synaptophysin, chromogranin and neuron specific enolase.  
MUCINOUS CARCINOMA 
             This is a specific category of adenocarcinoma. It can be 
diagnosed only when the tumour contains more than 50% of extracellular 
mucin. These tumours are commonly from large intestine, breast, ovary, 
pancreas but can occur anywhere along the gastrointestinal tract. It can 
also be a mucinous broncheolo-alveolar carcinoma 
 There are two histological patterns seen in mucinous carcinomas: 
1) Tumour cells floating in pools of mucin  
2)  The individual tumour cells are tall columnar with 
intracytoplasmic mucin. 
RENAL CELL CARCINOMA 
          The clear cell carcinoma of kidney infrequently metastasizes to the 
liver. Here, the cells are clear with bland nuclei and abundant blood 
vessels in the stroma. The other types are papillary renal cell carcinoma 
and chromophobe renal cell carcinoma. 
MELANOMA 
Melanomas are called as the great mimics in pathology. The 
morphology of the tumour cells in melanoma is so variable that any 
carcinoma can under into the differential diagnosis. Moreover, many 
patients present with metastasis long after the primary has been 
diagnosed.   
But, liver is an infrequent site for metastasis of melanoma, 
accounting for appropriately 2.2%. Cells can be identified by intranuclear 
inclusions and prominent nucleoli.  
LYMPHOMA 
              The appearance of lymphoma is based on the type of lymphoma. 
Diffuse large B cell lymphomas are the first among lymphomas to 
metastasise to the liver; they are easily diagnosed by their large size and 
nuclear and chromatin characteristics. 
  Follicular lymphomas, mucosa associated lymphoid tissue (MALT) 
lymphomas and small lymphocytic lymphomas are the other types of 
lymphomas; but there is difficulty in diagnosing these tumours based on 
morphology alone; and the clinician should be asked regarding any 
history of lymphoma in the patient. 
SARCOMA 
The most common spindle cell tumours to secondarily involve the 
liver are gastrointestinal stromal tumours and leiomyosarcomas. The 
gastrointestinal stromal tumours show spindle cells with moderate 
amount of eosinophilic cytoplasm and oval nucleus; nuclear 
pleomorphism may be noted. The tumour cells show positivity for c-kit in 
the cytoplasm. 
  Leiomyosarcomas reveal tumour cells which are highly 
pleomorphic when compared to gastrointestinal stromal tumours. In 
difficult cases immunohistochemistry with desmin and smooth muscle 
actin may be useful.  
 
 
MISCELLANEOUS TUMOURS 
  Urothelial carcinomas can also metastasize to the liver. They 
show cells that are seen in sheets and the cytoplasm is eosinophilic to 
amphophilic with elongated grooved nucleus. 
ROLE OF IMMUNOHISTOCHEMISTRY IN HEPATIC 
NEOPLASMS: 
HEPATOCELLULAR CARCINOMA VERSUS METASTATIC 
NEOPLASMS: 
Differentiating hepatocellular carcinoma from other neoplasms of 
the liver can be difficult and is often challenging in core and fine needle 
aspiration biopsies. 
  Several immunohistochemical markers are available which aid in 
this differential diagnosis. 
DIFFERENTIAL DIAGNOSTIC CONSIDERATIONS    
The most commonly encountered differential diagnostic challenge 
in the liver is hepatocellular carcinoma versus intrahepatic 
cholangiocarcinoma and metastatic malignancies like neuroendocrine 
tumours, renal cell carcinoma, adrenocortical carcinoma, melanoma and 
epithelioid angiomyolipoma.  
Lau SK and Prakash et al in 2002
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 evaluated Hep Par1 along with 
other IHC markers to differentiate hepatocellular carcinoma, 
cholangiocarcinoma and metastatic adenocarcinoma. 42 cases of HCC, 9 
cases cholangiocarcinoma and 56 cases of metastatic adenocarcinoma (24 
colon, 15 pancreas, 8 ovary, 5 breast and 4 stomach) were studied. 
  Hep Par1 was found to be a good marker, being both sensitive and 
specific for HCC, accounting for most of the cases, approximately 89% 
showing positivity; also only about 13% of metastatic carcinoma cases 
and none of the cholangiocarcinoma cases were positive for this marker.  
The markers p-CEA, CD10 and villin were found to be more specific for 
HCC since they were negative in all other malignancies. 
           Absence of monoclonal carcino-embryonic antigen and MOC-31 
staining was observed characteristic for hepatocellular carcinoma. 
Cytokeratin 7 and Cytokeratin 20 were found to be useful in the 
diagnosis, especially in cases of metastatic adenocarcinomas arising in 
the colon. 
COMMONLY USED MARKERS: 
HEP-PAR 1: (Also known as hepatocyte antigen): 
Hep-Par 1 is a monoclonal antibody that is considered as the most 
sensitive and specific immunohistochemical marker for hepatocellular 
carcinoma. It was first developed from failed allograft liver. Hep Par 1 
gives a diffuse cytoplasmic granular staining pattern in both normal and 
neoplastic hepatocytes.  
But Hep Par 1 is not helpful in differentiating benign from 
malignant hepatocellular lesions because of its positive staining pattern in 
normal liver and in adenomas.  
ADVANTAGES 
a) It is highly sensitive and specific (both >80%). 
b) It may be negative in metastatic adenocarcinomas from biliary tree, 
pancreas, colorectum, breast, urinary bladder and prostate. 
c) The tumours which may be confused with hepatocellular carcinoma 
by light microscopic, such as neuroendocrine neoplasms, renal cell 
carcinoma, malignant melanoma and epithelioid angiomyolipoma, 
are usually negative, of only focally positive for Hep Par 1. 
 
PITFALLS IN DIAGNOSIS 
a) The sensitivity of Hep Par 1 is low (50% or less) in poorly 
differentiated carcinomas.   
b) In about 20% of hepatocellular carcinomas, Hep Par 1 yields only 
patchy staining and so needle biopsies may be negative for the 
marker. 
c) Certain carcinomas have hepatoid morphology (Eg. gastrointestinal 
tract and pancreas); and these are positive for Hep Par 1. 
ALPHA FETOPROTEIN (AFP) 
AFP was first identified in 1956 on paper electrophoregrams by 
Bregstrand and Czar. After a few years, it was concluded that Alpha Feto 
Protein is a useful marker in differentiating hepatocellular carcinoma 
from metastatic deposits in liver. 
 Other than hepatocellular carcinoma, AFP was also found to be 
associated with teratoblastoma of the testis and ovarian germ cell 
tumours. 
AFP is an oncofetal protein produced by the liver and visceral 
endoderm of yolk sac. It is specifically expressed in tumour cells of 
hepatocellular differentiation, provided germ cell tumours are excluded.  
But AFP has a patchy staining and low sensitivity of 30 to 50%. 
Because of low sensitivity and availability of better antibodies, AFP is 
not considered as a good option for diagnosis.  
Porcell et al in 2000
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 studied 57 previously characterized hepatic 
neoplasms, 13 cases were hepatocellular carcinomas. Alpha Fetoprotein 
was detected in 4 of these 13 cases (30%). 
In a study by Lau SK Prakash S et al in 2002
28
, 42 cases of 
hepatocellular carcinomas were studied using a panel of markers 
including Alpha Fetoprotein, Hep Par 1, p-CEA, CD10 and villin. They 
found that Alpha Fetoprotein was observed in one third of the cases. 
GLYPICAN -3 (GPC-3) 
Glypican-3 is a membrane anchored heparan sulphate proteoglycan 
and it is expressed in fetal liver and placenta normally but not in adults. 
Studies have shown that GPC-3 is positive in 64% to 90% of 
hepatocellular carcinomas and negative in normal liver or benign hepatic 
lesions like adenomas. 
 
 
 
 
ADVANTAGES 
a) It is highly sensitive (about 80%). 
b) More useful and sensitive than Hep Par 1 for poorly differentiated 
hepatocellular carcinoma. 
c) It can be used to distinguish benign from malignant hepatocellular 
lesions since it is negative in normal liver and hepatic adenomas.  
PITFALLS IN DIAGNOSIS 
a) It's a relatively newer antibody and more extensive studies in 
other or needed to confirm its reported high sensitivity. 
b) It may be negative in well differentiated hepatocellular 
carcinomas. 
c) GPC-3 is not very specific because it gives positive staining 
pattern in melanoma and non-seminomatous germ cell tumours 
such as yolk sac tumour and choriocarcinoma. 
POLYCLONAL CARCINOEMBRYONIC ANTIGEN (CEA) 
In a study conducted by Mack and Zarbo RJ et al in 1993
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, who 
studied 56 hepatocellular carcinomas, 71% of hepatocellular carcinomas 
revealed a bile canalicular staining pattern with pCEA. 
CEA is a glycoprotein which is present in fetal epithelial cells and 
in normal adult cells. Polyclonal carcinoembryonic antigen (p-CEA) 
yields diffuse cytoplasmic staining many cases of adenocarcinoma.  
          In hepatocellular carcinoma, it gives a characteristic canalicular 
pattern which is seen in 60% to 90% of cases. This staining is due to 
cross reaction with biliary glycoprotein. 
  This characteristic canalicular pattern of hepatocellular carcinoma 
is absent in adenocarcinoma. Monoclonal CEA also shows positivity in 
adenocarcinomas, but its sensitivity is low (around 80%). Hepatocellular 
carcinoma is negative for monoclonal CEA. 
ADVANTAGES 
a) The characteristic canalicular staining pattern is specific for 
hepatocellular carcinoma. 
b) p-CEA has sensitivity of more than 80% in well and moderately 
differentiated carcinoma. 
 
 
 
PITFALLS IN DIAGNOSIS 
a) Interpretation of cytoplasmic and canalicular patterns of staining is 
difficult in some cases.  
b) Around 50% of hepatocellular carcinomas can show diffuse 
cytoplasmic staining for p-CEA, in addition to canalicular pattern. 
c) Similar to Hep Par 1, its sensitivity is low (25 to 50%) in poorly 
differentiated hepatocellular carcinoma. 
MOC – 31 
MOC-31 is an immunohistochemical marker which was found to 
be helpful to separate the cases of metastatic adenocarcinomatous 
deposits and mesothelioma. It is noted in 80 to 100% cases of 
cholangiocarcinoma and metastatic adenocarcinoma from a variety of 
sites, such as colorectum, pancreas, stomach, lung, breast and ovary. 
CD10 AND VILLIN 
CD10 and villin, like p-CEA show canalicular pattern in 
hepatocellular carcinoma. They are not as good as p-CEA, since they are 
less sensitive. (50% for CD10 and 20% for villin). 
 
 
TTF-1 
TTF-1 is normally expressed in the follicular epithelial cells of 
thyroid and also in the lung; and so, in tumours that arise from them. 
Cytoplasmic TTF-1 staining is noted in about 10% of hepatocellular 
carcinomas. 
CYTOKERATINS(CK) 
CK8 and CK18 are expressed in normal and neoplastic 
hepatocytes; whereas CK7, CK19 and CK20 are negative in these sites. 
CK cocktail AE1/AE3 shows only patchy staining except in cases of 
poorly differentiated hepatocellular carcinomas which may show clusters 
of positive cells. 
CK7 and CK20 are negative in most cases of hepatocellular 
carcinomas.  
Nearly 75% of hepatocellular carcinomas are CK7 and CK20 
negative, 20% are CK 7 positive and CK20 negative and 5% are CK7 
positive and CK20 positive. Like AE1/AE3, CK7 tends to be stronger in 
poorly differentiated hepatocellular carcinoma.  
 Hence, the commonly used keratin antibodies (AE1/AE3, 
CAM5.2, CK7, CK20) can be expressed in both hepatocellular carcinoma 
and adenocarcinoma, limiting their value in this differential diagnosis. 
CK7 and CK20 are also useful in assessing the possible primary site once 
the diagnosis of adenocarcinoma is made. CK19 shows positivity in 85% 
to 100% of cholangiocarcinoma and it is negative in most hepatocellular 
carcinomas. 
CD34 
CD34 is normally not expressed in the sinusoids in the normal liver 
but the sinusoid-like vasculature in hepatocellular carcinoma often shows 
strong expression of CD34, which is due to the capillarization of 
sinusoids leading to a change in the phenotype of endothelial cells.  
This sinusoidal pattern of CD34 expression is specific for 
hepatocellular carcinoma because it is not seen in adenocarcinoma. But it 
has a low sensitivity of 20% to 40%. 
 It is not useful in differentiating benign from malignant 
hepatocellular lesions because it can also be seen in focal nodular 
hyperplasia and hepatic adenomas. But CD34 may be useful to 
differentiate well differentiated hepatocellular carcinoma from a normal 
or cirrhotic liver in case of small biopsy specimens.    
Albumin in situ hybridization is specific and sensitive (>90%) for 
hepatocellular differentiation. Combination of albumin in situ 
hybridization and Hep Par1 can yield 100% sensitivity for diagnosis of 
hepatocellular carcinoma. However, the use of this test is limited by its 
restricted availability
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Materials and Methods 
MATERIALS AND METHODS 
Cases  diagnosed  as  hepatic  malignancy  on  liver  biopsy  
specimens  received  in  the Department  of  Pathology,  Coimbatore  
Medical  College  Hospital  during  a  period  from  July 2011  to  July 
2012  were  taken. 
INCLUSION CRITERIA 
1)  Liver biopsy specimens reported as dysplastic and neoplastic lesions 
of liver. 
2)  Patient age more than 12 years.  
EXCLUSION CRITERIA 
1)  Liver biopsy specimens other than dysplastic and neoplastic lesions 
of liver. 
2)  Patient age less than 12 years.  
Sections were cut at 4 microns  thickness. Coated  slides  were  
used  and  the  slides kept  in  incubation  at  58 degrees  overnight. The 
initial sections were stained with hematoxylin and eosin stain.  
The  unstained  slides  were  used  for  running reticulin  stain  by  
Gomori’s  method  and  immunohistochemistry  by  a  two-step  indirect 
technique. 
METHOD OF HEMATOXYLIN AND EOSIN STAINING 
Reagents used : 
1. Erhlich's Hematoxylin solution  
2. Eosin Y solution 1 % 
3. Acid Alcohol  solution 1% 
Procedure : 
1. Deparrafinize  the sections  
2. Immerse the sections in xylene for 30 minutes 
3. Then place in isopropyl alcohol for 15 minutes 
4. Wash in tap water 
5. Stain the sections with Erhlich's Hematoxylin for 10-15 minutes  
6. Wash in tap water 
7. Differentiate in 1% acid alcohol solution – 2 to 3 dips 
8. Blueing for 10 minutes.  
9. Counter stain with 1% eosin solution - 2 to 3 dips  
10. Wash in tap water  
11. Air dry the sections 
12. Xylene – Mount  
 These hematoxylin and eosin stained sections are then observed 
and a diagnosis is obtained based on histomorphological features.  
METHOD OF RETICULIN STAIN 
                Gomori’s method 
PRINCIPLE 
            Reticulin  staining  is  based  on  the  high  content  of  hexose  
sugars  in  reticulin. 
  Reticulin  fibres  have  little  natural  affinity  for  silver  solutions  
and  hence  they  are  pretreated to  produce   sensitized  sites  where   
silver  will  deposit. 
REAGENTS USED 
1) Ammoniacal  silver  solution 
2) 0.5%   KMnO4 
3) 2% Potassium  metabisulfite 
4) 2% Ferric Ammonium  Sulfate 
5) 20%  Formalin 
6) 0.25 Gold  chloride 
7) 2% Sodium  thiosulphate 
 
 
PREPARATION OF  AMMONIACAL  SILVER  SOLUTION 
10% Silver  nitrate : Add  1gm  of  silver  nitrate  to  10 ml  of  
distilled  water. 
10% Aqueous  solution  of  KOH : Add  1 gm  of  KOH  to  10 ml  
of  distilled water. 
Mix  10 ml  of  10% silver  nitrate  solution  with  2.5 ml  of  10%   
aqueous solution  of  KOH. 
Then, add 28% ammonia drop by drop until the precipitate is 
completely dissolved. Add an equal amount of distilled water. 
PROCEDURE 
1) Deparrafinze tissue sections in xylene for 30 minutes. 
2) Wash in absolute alcohol for 10 minutes with 2 changes. 
3) Place  in  tap  water  for  10 minutes  and  subsequently  in  
distilled  water  for  5 minutes. 
4) Oxidise the sections in KMnO4 solution. 
5) Wash in tap water and differentiate in potassium metabisulfite. 
6) Sensitize in ferric ammonium sulphate for 1 minute. 
7) Wash  in  tap  water  for  2  minutes  and  distilled  water  for  5  
minutes. 
8) Impregnate with silver solution. 
9) Rinse in distilled water and then reduce in formalin solution. 
10) Wash  in  tap  water  and  tone  in  gold  chloride  for  10  minutes. 
11) Then reduce in potassium metabisulfite and fix in sodium 
thiosulfate.                    
12)  Wash in tap water, alcohol and xylene. 
13) Air dry and mount with DPX. 
RESULT 
Reticulin fibres are stained black in a colourless background. 
METHOD OF IMMUNOHISTOCHEMISTRY 
METHOD 
Two-step indirect technique. 
PRINCIPLES OF THE PROCEDURE 
This technique is based on the detection of antigens in the cells and 
tissues with the help of a two-step process: 
1. Specific epitopes used to bind the primary antibody followed by, 
2. Colorimetric reaction used to detect this binding.  
 The tissue sections which are paraffin embedded are taken and 
antigen retrieval is done. This is performed using a microwave. The tissue 
sections are placed in appropriate buffer solutions and then subjected to 
heating in a microwave. This helps to retrieve the antigenicity of the cells.  
Now the sections are treated with power block to block the       
non-specific interactions between the proteins. 
REAGENTS USED 
1) Peroxide Block: 3%hydrogen peroxide in water. 
2) Power Block Reagent: A highly effective universal protein 
blocking reagent. Contains casein and propriety additives in PBS 
with 15mM sodium azide. 
3) Chromogen: DAB-3,3’-diaminobenzidine. 
4) Liquid DAB Substrate: Comprises Tris buffer containing the 
peroxide and stabilizers. 
5) Super Enhancer Reagent. 
6) Poly-HRP Reagent. 
7) Counter stain: Mayer’s Hematoxylin. 
8) Buffer solutions:  
 
TRIS BUFFER: (ph -7.6) 
TRIS Buffer salt: 0.605 gm 
Sodium chloride: 8 gm 
Distilled water: 1000 ml 
1N Hydrochloric acid: 3 ml 
 
 
CITRATE BUFFER: (ph-6.0) 
Trisodium citrate: 2.94 gm 
Distilled water: 1000 ml 
1 N Hydrochloric acid: 5 ml 
TRIS EDTA: (ph-9.0) 
TRIS Buffer salt: 6.05 gm 
Disodium EDTA: 0.744 gm 
Distilled water: 1000 ml          
PROCEDURE 
1) Deparaffinise the sections in xylene for 30 minutes. 
2) Wash in absolute alcohol for 5 minutes with 2 changes. 
3) Wash the slides in tap water for 10 minutes. 
4) Rinse in distilled water for 5 minutes. 
5) Antigen retrieval is done by placing the slides with appropriate 
buffer solution in microwave: Medium-10 minutes: High-10 
minutes. 
6) Cool to room temperature and rinsed in distilled water. 
7) Wash in TBS buffer for 5 minutes with 2 changes. 
8) Treat with Peroxide Block for 10 minutes. 
9) Wash in TBS buffer for 5 minutes with 2 changes. 
10) Treat with Power Block for 10 minutes. 
11) Drain the slides and cover with primary antibody (supplied from 
DAKOCYTOMATION) for 2 hours. 
12) Wash in TBS buffer for 5 minutes with 2 changes. 
13) Cover the slides with Super Enhancer for 30 minutes. 
14) Wash in TBS buffer for 5 minutes with 2 changes. 
15) Apply Poly HRP reagent and leave for 30 minutes. 
16) Wash in TBS buffer for 5 minutes with 2 changes. 
17) Treat with DAB Chromogen with Substrate buffer for 5 to 8 
minutes. 
18) Wash in TBS for 5 minutes with 2 changes. 
19) Wash the slides in tap water for 5 minutes. 
20) Counterstain with Mayer’s Hematoxylin for 1 minute. 
21) Wash in tap water for 5 minutes. 
22) Air dry and mount with DPX. 
Tumour cells are scored positive if there is golden brown 
cytoplasmic staining in the neoplastic cells. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Observation  
 
OBSERVATION 
A  total  of  34  liver  biopsies  were  reported  in  the  Department  
of  Pathology, Coimbatore  Medical  College  Hospital  over  a period  
from  July 2011  to  September 2012. Out of these, 26 cases were 
reported as hepatic neoplasms. Among  these  hepatic neoplasms,  13 
cases  were  reported  as  hepatocellular  carcinomas  and  13  cases  as 
metastatic  carcinomatous  deposits  in  the  liver. Thus,  the  incidence  of  
hepatic  neoplasms among  the  liver  biopsy  specimens  received  was  
76.4%. 
 
TABLE-1 
 
INCIDENCE OF HEPATIC MALIGNANCY IN DIFFERENT AGE 
GROUPS 
S.No. 
AGE GROUP 
(Yrs) 
No. OF 
CASES 
PERCENTAGE 
(%) 
1. <40 0 0 
2. 40-50 7 27 
3. 51-60 9 35 
4. 61-70 7 27 
5. >70 3 11 
 TOTAL 26 100 
 
 
CHART-1 
 
INCIDENCE  OF  HEPATIC  MALIGNANCY  IN  DIFFERENT  
AGE  GROUPS 
 
 
 
In  the  above  frequency  table, it  is  observed  that  the  incidence  
of  hepatic malignancies  was  high (35%)  in  the  age  group  of  51  to  
60 yrs,  followed  by  the  age  group  of 41-50 yrs (27%),  61-70 yrs 
(27%)  and >70 yrs (11%). 
TABLE-2 
 
INCIDENCE  OF  HEPATIC  MALIGNANCY  IN  DIFFERENT  
SEX  GROUPS 
S.No. SEX No. OF CASES 
PERCENTAGE 
(%) 
1. Male 18 69 
2. Female 8 31 
 TOTAL 26 100 
 
CHART- 2 
 
INCIDENCE  OF  HEPATIC  MALIGNANCY  IN  DIFFERENT  
SEX  GROUPS 
 
It  is  observed  from  the  above  table  that  the  incidence  of  
hepatic  neoplasms was  comparatively  high  in  males (69%)  than  in  
females (31%). 
In  the  present  study,  among  13  cases  reported  as  
hepatocellular  carcinomas  in Hematoxylin  and  Eosin  stained  sections,  
11  cases  were  positive  for  Alpha Fetoprotein immunohistochemically,  
giving  a  sensitivity  of  84%.  
Hep Par 1  expression  was  also  studied  in  all  cases  of  
hepatocellular  carcinomas. 
  12  out  of  13  cases  were  positive  and  only   1 case was  
negative; thus  the  sensitivity  of Hep Par 1  in  this  study  was  found  to  
be  92%. 
So,  it  is  observed  that  both  Alpha Fetoprotein  and  Hep Par 1  
are  good immunohistochemical  markers  for  the  diagnosis  of  
hepatocellular  carcinoma;  and  Hep Par 1 is  more  sensitive  than  
Alpha Fetoprotein. 
CHART- 3 
PERCENTAGE POSITIVITY OF ALPHA RETROPROTIEN 
(AFP) AND HEP PAR 1 EXPRESSIONS IN HEPATOCELLULAR 
CARCINOMA CASES 
 
Among  the  13  cases  reported  as  metastatic  carcinomas  of  
liver,  all  cases were  studied  using  the  immunohistochemical  markers  
Cytokeratin7  and  Cytokeratin20. 
TABLE 3 
EXPRESSION  OF  CYTOKERATIN7  AND  CYTOKERATIN20  
IN  METASTATIC  CARCINOMAS 
S.No. MARKERS 
No. OF 
POSITIVE 
CASES 
No. OF 
NEGATIVE 
CASES 
PERCENTAGE 
OF POSITIVE 
CASES (%) 
1. CYTOKERATIN7 7 6 54 
2. CYTOKERATIN20 3 10 23 
 
From  the  study,  the  following  observations  were  obtained: 
No.  of   Cytokeratin7  positive  and  Cytokeratin20  negative  
cases: 7 (54%) 
No.  of  Cytokeratin7  negative  and  Cytokeratin20  positive  
cases: 3 (23%) 
No.  of  Cytokeratin7  negative  and  Cytokeratin20  negative  
cases: 3 (23%) 
No.  of  Cytokeratin7  positive  and  Cytokeratin20  positive  cases: 
0 (0%) 
 CHART-4 
EXPRESSION  OF  CYTOKERATIN7  AND  CYTOKERATIN20  
IN  METASTATIC  CARCINOMAS 
 
 
              Analysing  the  possible  sites  of  primary  tumour  in  these  13  
cases  of  metastatic carcinomas : 
TABLE 4 
PATTERNS  OF  CYTOKERATIN  EXPRESSION  IN  VARIOUS  
TYPES  OF  METASTATIC  TUMOURS 
CYTOKERATIN 7 
POSITIVE/ 
CYTOKERATIN 20 
POSITIVE TUMOURS 
CYTOKERATIN 7 
POSITIVE/ 
CYTOKERATIN 20 
NEGATIVE TUMOURS 
Urothelial  carcinoma 
Pancreas 
Biliary  tract 
Esophagus/Stomach 
Mucinous  carcinoma 
(ovarian,  colon, mucinous  
broncheoalveolar) 
Breast 
Lungs                 
Esophagus/Stomach 
Pancreas 
Biliary  tract 
Ovary (nonmucinous) 
Endometrium 
CYTOKERATIN 7 
NEGATIVE/ 
CYTOKERATIN 20 
POSITIVE TUMOURS 
CYTOKERATIN 7 
NEGATIVE/ 
CYTOKERATIN 20 
NEGATIVE TUMOURS 
Colorectal Prostate 
Renal  Cell  Carcinoma 
Adrenal  Cortical  Carcinoma 
 
           In  the  study,  the  most  common  expression  is  cytokeratin 7 
positive/ cytokeratin 20 negative  expression  which  is  observed  in  
54%  of  cases,  followed  by  cytokeratin 7 negative/ cytokeratin 20 
positive  cases (23%),  cytokeratin 7 negative/ cytokeratin 20 negative 
(23%) and  cytokeratin 7 negative/ cytokeratin 20 negative (0%)  
expressions. 
         This  leads  to  an  observation  that  the  most  common primary  
sites  of  tumours  to metastasize  to  the  liver  are  esophagus,  stomach, 
breast,  lungs,  pancreas,  biliary  tract,  ovary  and  endometrium. 
          At  this  point,  it  is  worth  mentioning  about  the  size  of  liver  
biopsy  specimens.  The  size of  the  liver  biopsy  specimens  received  
in  the  laboratory  during  the  period  of  the  study  was less  than  1.5 
cm  which  did  not  meet  the  required  adequacy  (atleast 1.5 cm).  So,  
only  the more  commonly  used  markers  Alpha Fetoprotein,  Hep Par 1,  
Cytokeratin 7  and  Cytokeratin 20  could  be  studied.  
         Special  stain  with  reticulin  by  Gomori’s  method  was  done  in  
10   difficult  cases  to differentiate   benign  from  malignant  lesions. 
         Reticulin  fibres  in  the  benign  processes  revealed  one-cell  thick  
liver  plates; whereas  in dysplastic  and  carcinomatous  deposits, they  
showed  increased thickness of liver cell plates, which appeared to be 
more than two cell-thick , normal being one-cell thickness. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colour Plates  
 
 Fig. 1 : Low Power view showing well differentiated Hepatocellular 
Carcinoma composed of tumor cells arranged in 2- to 3- cell thick 
trabeculae (10x) 
 
 
 Fig. 2 : High Power view showing polygonal tumor cells with nuclear 
pleomorphism and high nuclear to cytoplasmic ratio (40x) 
 
 Fig. 3 : Hepatocellular Carcinoma showing tumor cells which are 
strongly positive for Alpha Feto-protein (40x) 
 
 
Fig. 4 : High power view showing cytoplasmic granular positivity of 
Hep par1 in the tumor cells (40x) 
 Fig. 5 : High power view showing sheets of tumor cells with moderate 
eosinophilic cytoplasm and nuclear atypia (40x) 
 
Fig. 6 : Immunohistochemical staining of hepatocellular carcinoma 
with Hep par1. The tumor cells are strongly positive for Hep par1 
with a cytoplasmic granular pattern (40x) 
 
  
 
 
 
 
 
Fig. 7 : Immunohistochemical staining of hepatocellular carcinoma 
with Alpha Feto-protein. Most tumor cells express Alpha Feto-
protein in the cytoplasm (40x) 
 Fig. 8 : Low power view showing tumor cells of hepatocellular 
carcinoma (10x) 
 
 
Fig. 9 : High power view of hepatocellular carcinoma with nuclear 
pleomorphism and atypia (40x) 
 Fig. 10 : Immunohistochemical staining of hepatocellular carcinoma 
with Hep par1 shows a cytoplasmic granular pattern representing 
hepatocellular differentiation (10x)  
 
 
 Fig. 11 : Tumor cells of hepatocellular carcinoma showing 
diffuse cytoplasmic positivity for Alpha Feto-protein  (40x) 
 Fig. 12 : High power view of metastatic adenocarcinomatous deposits 
in liver showing malignant tumor cells arranged in glandular pattern 
(40x)  
  
 
Fig. 13 : The tumor cell in metastatic deposits showing strong 
cytoplasmic positivity for Cytokeratin 7 (40x)  
 Fig. 14 : Hepatocellular carcinoma showing tumor cells with nuclear 
pleomorphism (10x) 
 
Fig. 15 : The tumor cells are strongly positive for Alph Feto-protein 
(40x) 
  
 
 
 
 
Fig. 16 : Well-differentiated hepatocellular carcinoma showing a 
compact pattern with inapparent sinusoids (Reticulin Stain) (40x)  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
DISCUSSION 
               26  cases  of  hepatic  malignancies  during  the  period  from  
July  2011  to  July  2012 were  studied. 
Statistical  data  of  percentage  positivity  of  Alpha Fetoprotein  
and  Hep Par 1  in primary  hepatic  malignancies  and  Cytokeratin 7  and  
Cytokeratin 20  in  metastatic carcinomas  of  the  liver  were  studied ,  
and  compared  with  those  in  the  literature. 
HEP PAR 1 EXPRESSION 
According   to  a  study  by  Lau  SK et al  in  2002
28
,  who  
evaluated  Hep Par 1  in  42 cases  of  hepatocellular  carcinomas,  38  
cases (90%)  were  positive. 
Zhen Fan et al  in  2003
42 
 studied   Hep Par 1  expression  in  19  
cases  of  hepatocellular   carcinomas  and  found  positivity  in  18   cases 
(94%). 
In  a  study  by  Pozharisski KM et al  in  2008
46
,  55  primary  
hepatic  tumours  were studied;  Hep Par 1  was  positive  in  all  the  
cases (100%). 
 
According   to  a  study  by  Karabork A et al  in  2010
51
,  Hep Par 
1  was  positive  in 95.6%  cases  among  68  cases  studied. 
In  the  present   study,  among  the  13 cases  diagnosed  as  
hepatocellular carcinoma,  12  cases (92%)  were  positive for  Hep Par 1,  
which  was  comparable  with  the  other  studies.  
TABLE-5 
COMPARISON OF % POSITIVITY OF HEP PAR 1 IN 
DIFFERENT STUDIES 
STUDY GROUP YEAR 
No. OF CASES 
STUDIED 
% POSITIVITY 
OF 
HEP PAR 1 
Lau SK et al            2002                42              90 
Zhen Fan et al            2003               19              94 
Pozharisski et al            2008               55             100 
Karabork et al            2010               68             95.6 
Present Study            2011               26             92 
 
Hence  it  is  observed  that  Hep Par 1  is  a  useful  marker  in  the  
diagnosis  of  hepatocellular  carcinoma. 
 
 
  ALPHA FETOPROTEIN EXPRESSION 
Porcell et al  in  2000
41 
 studied   57  previously  characterized  
hepatic  neoplasms,  13 cases  were  hepatocellular  carcinomas. Alpha 
Fetoprotein  was  detected  in  4  of   these  13 cases (30%). 
In  a  study  Lau SK Prakash S et al  in  2002
28
,  42 cases  of  
hepatocellular  carcinomas were  studied  using  a  panel of  markers  
including  Alpha Fetoprotein,  Hep Par 1,  p CEA,  CD10 and  villin. 
They  found  that  Alpha Fetoprotein  was  observed  in  one third  of  the  
cases. 
According   to  a  study  by  Ali S. Sawan et al  in  2009
38
,  41  
cases  histologically diagnosed  liver  biopsies  were  studied  including  
hepatocellular  carcinoma, cholangiocarcinoma  and  metastatic 
carcinoma;  Alpha Fetoprotein  was  positive  in  43.7%  of  
hepatocellular  carcinoma  cases. 
                    In  the  present  study, 11  out  of  13  cases  of  
hepatocellular  carcinomas  stained positive  for  Alpha Fetoprotein;  its  
sensitivity  being  84%  which  is   more  than  that  found  in other  
studies. 
TABLE 6 
COMPARISON  OF %  POSITIVITY  OF  ALPHA 
FETOPROTEIN  EXPRESSION  WITH OTHER  STUDIES 
STUDY GROUP YEAR 
No. OF CASES 
STUDIED 
% POSITIVITY OF 
ALPHAFETO 
PROTEIN 
Porcell et al 2000 13 30 
Lau SK Prakash 2002 42 33 
Ali S.Sawan 2009 41 43.7 
Present Study 2011 26 84 
Thus,  Hep Par 1  is  more  sensitive  than  Alpha Fetoprotein  in  
the  diagnosis  of  Hepatocellular  carcinoma. 
CYTOKERATIN 7  AND  CYTOKERATIN 20  EXPRESSIONS  IN  
METASTATIC  CARCINOMA: 
Rullier A et al  in  2000
59 
 studied  31  cases  of  colorectal  
carcinomas  and cholangiocarcinomas.  Cytokeratin 20  was  positive  in  
all  cases  of  colorectal  carcinomas.  
Cholangiocarcinomas  were   positive  for  cytokeratin 7  and  
cytokeratin 20  in  96%  and  70%  cases  respectively. 
In  a  study  by  Ali S. Sawan et al  in  2009
38
,  which  included  41  
cases  of  histologically diagnosed  liver  biopsies  including  primary 
liver malignancies, cholangiocarcinoma  and secondaries in the hepatic 
parenchyma, Cytokeratin 7  positive  and  cytokeratin 20  negative 
expression  were  identified  in  100 percent  of  cholangiocarcinomas,  
one  metastatic pancreatic  carcinoma   and  all  metastatic  gastric  
carcinomas.  It  was  also  found  that  cytokeratin 7  negative  and  
cytokeratin 20  positive  expression  indicates   colorectal  carcinoma  
metastatic  to  the  liver  and  that  cytokeratin 7  expression  excludes  
hepatocellular carcinoma. 
In  the  present   study, cytokeratin 7  and  cytokeratin 20  were  
positive  in  7 and 3 cases  respectively  in  the  13 metastatic carcinomas  
studied.  Also,  cytokeratin 7 positive/ cytokeratin 20  negative expression  
is  the  most  common  observation (54%)  in  this  study which  indicates  
that  that  the  most  common  tumours  to  metastasize  to  the  liver  are  
from esophagus,  stomach,  biliary  tract,  pancreas,  breast,  lungs,  ovary  
and  endometrium. 
      Ideally  a  panel  of  markers  including  CD10, p CEA,  
Cytokeratin 19,  MOC-31  and villin   should  be  used  to  diagnose  
hepatocellular  carcinoma  and  to  assess the possible location of the 
origin the metastatic tumours with  more  accuracy;  but  only  the  more  
common  and reliable  markers  Alpha Fetoprotein,  Hep Par 1,  
Cytokeratin 7  and  Cytokeratin 20  were included  in  the  present   study.  
This  is  because  of  the  availability  of  very  limited  tissue  in  the 
biopsy  specimen  which  warranted  the  judicious  use  of  markers. 
Special  stain  study  with  reticulin  by  Gomori’s  method  was  
also  done. It  was  found to  be  useful  in  differentiating  benign  from  
malignant  lesions  of  liver. 
  
 
 
                       
 
 
 
                                    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary  
SUMMARY 
This  is  a  prospective  study  on  hepatic  neoplasms  reported   on  
liver  biopsy specimens  received  in  the  Department  of  Pathology,  
Coimbatore  Medical  College  Hospital, Coimbatore  over  a  period  of  
one  year  from  July 2011  to  July 2012. 
26  out  of  34  liver  biopsy  specimens  received  were  reported  
as  hepatic  neoplasms; 13  cases  were  hepatocellular  carcinomas  and  
13  were  metastatic tumours  in the  liver. 
All 13  cases  of  hepatocellular  carcinomas  were  studied  using  
the immunohistochemical  markers  Alpha Fetoprotein  and  Hep Par 1.  
Alpha Fetoprotein  was positive  in  11 cases (84%)  and  Hep Par 1  was  
positive  in  12  cases (92%). 
Cytokeratin 7 and Cytokeratin 20 were studied in 13 cases of  
metastatic  tumours. 
  Majority  of  tumours  showed  Cytokeratin 7 positive/ cytokeratin 
20  negative  expression  (54%), which  indicates  that  the  most  
common  primary  sites  were  esophagus,  stomach,  pancreas,  biliary  
tract,  breast,  lungs,  ovary  and  endometrium. 
If   adequate  liver  biopsy  specimen  is  received (atleast  1.5 cm),  
an  expanded  panel  of  markers  can  be  used  to  identify  the  primary  
site  of  tumour  with  more  accuracy. 
Reticulin  stain  was  also  done  in  difficult  cases  to  differentiate  
benign  from  malignant  lesions  of  the  liver,  which  was  found  to  be  
useful.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Conclusion 
CONCLUSION 
       Liver biopsy is an essential investigational procedure done for 
evaluation and management of patients with reference to the histological 
assessment of the liver. The liver disease can be diagnosed by the widely 
available, sensitive and relatively accurate blood investigations. But the 
valuable diagnostic tool which remain as gold standard in the liver 
biopsy. 
An adequate sample measures 1.5 cm long and 1.2 to 2mm in 
thickness. Histologically, it should contain atleast 6 to 8 portal triads.   
           The distinction  of  hepatocellular  carcinoma  and  other 
neoplasms  involving the liver  can  be  at  times  difficult  and  
challenging.  Immunohistochemistry  is  useful  in  such cases  especially  
to  differentiate  primary  from  matastatic  hepatic  neoplasms. 
            The  immunohistochemical  markers  Alpha Fetoprotein  and  Hep 
Par 1  usually indicate  malignancy  in  hepatocellular  nodule  and  
hepatocytic  histogenesis  of  a malignancy.  Hep Par1 is a more sensitive  
marker  than  Alpha Fetoprotein. 
      Cytokeratin 7  and  Cytokeratin 20  are  the  markers  to  assess  the  
probable  sites of   tumours  in  cases  of  metastasis. From  this  study,  
the  most  common  sites  of  primary   tumours  are  esophagus, 
stomach,pancreas, breast,  biliary  tract,  ovary  and endometrium.  
If  adequate  tissue  is  available,  an  additional  panel  of  markers  
can  be  used including   Glypican 3,  CD10,  pCEA,  Cytokeratin 19, 
villin  to  identify  the  primary  site  of tumour  with  more  accuracy.  
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices  
ANNEXURE  
PROFORMA 
 
COIMBATORE MEDICAL COLLEGE   
DEPARTMENT OF PATHOLOGY 
COIMBATORE  
 
Particulars of the Patient : 
Name :  Hospital : 
Case No. :  Date : 
Age/Sex :  I.P. No. : 
Address :  Ward No. : 
Occupation :  Religion : 
 
 
Presenting Complaints and  Duration : 
 
Abdominal Pain +/- 
Nausea / Vomiting +/- 
Fever +/- 
Loss of Appetite / Loss of Weight +/-  
Bleeding Diathesis +/- 
 
Past History : 
 
Previous History of Hepatitis infection +/- 
Transfusions +/- 
Drug History +/- 
Chronic Diseases +/- 
 
Family History : 
 
Recurrent Jaundice +/- 
Malignancy +/- 
 
Personal History : 
 
Diet / Appetite / Bowel and Bladder Habits 
Sleep / Alcohol Intake 
 
Menstrual History : 
 
General  Physical Examination : 
 
Built  : Febrile / Afebrile  : 
Nourishment  : Pallor : 
Conscious : Jaundice : 
Weight : Cyanosis : 
Pulse  : Clubbing : 
Respiratory Rate : Lymphadenopathy : 
Pulse Rate : Edema  : 
 
Systemic Examination : 
P/A :  Hepatomegaly  
 Splenomegaly  
 Ascites 
 
CVS : RS :           CNS :               Musculo Skeletal System : 
 
 
 
Clinical Diagnosis : 
 
 Investigations : 
1) Complete Hemogram 
2) Liver Function Tests 
3) USG / CT Abdomen  
4) Upper / Lower GI Endoscopy 
 
Liver Biopsy Evaluation : 
 
Histopathological Diagnosis : 
 
Immunohistochemistry : 
 
Alpha Fetoprotein +/- 
 
Hep par1 +/-  
 
Cytokeratin 7 +/- 
 
Cytokeratin 20 +/- 
 
Final Diagnosis : 
 
 Primary or secondary neoplasm of liver. 
 
 If secondary malignancy – possible site of primary  
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 MASTER CHART  
S.NO. 
BIOPSY 
NO. 
IP 
NO. 
AGE SEX 
CLINICAL 
DIAGNOSIS 
HISTOPATHOLOGICAL 
DIAGNOSIS 
IMMUNO HISTOCHEMISTRY 
FINAL DIAGNOSIS 
AFP 
HEP PAR-
1 
CYTOKERATIN 7 
CYTO 
KERATIN 20 
1. 240/10 2353 48 M Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
TI TI + - Metastatic 
Adenocarcinomatous 
Deposits  
2. 1615/10 42758 54 M Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
TI TI - + Metastatic 
Adenocarcinomatous 
Deposits 
3. 2448/10 68472 59 F Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
- - - - Metastatic 
Adenocarcinomatous 
Deposits 
4. 2495/10 60665 78 M ? Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
5. 1019/11 29392 60 M ? Hepatoma Metastatic 
Adenocarcinomatous 
Deposits 
TI TI + - Metastatic 
Adenocarcinomatous 
Deposits 
6. 1198/11 30736 49 F Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
TI TI + - Metastatic 
Adenocarcinomatous 
Deposits 
7. 1378/11 33429 58 F ? Hepatoma Hepatocellular Carcinoma + - TI TI Hepatocellular Carcinoma 
8. 1444/11 52787 68 M Secondaries 
Liver 
Hepatocellular Carcinoma + - TI TI Hepatocellular Carcinoma 
9. 2331/11 53587 40 M ? Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
10. 3479/11 61487 45 M Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
TI TI + - Metastatic 
Adenocarcinomatous 
Deposits 
11. 4562/11 65432 65 M  Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
12. 4641/11 68716 62 M Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
- - - - Metastatic 
Adenocarcinomatous 
Deposits 
 13. 5308/11 70352 55 M ? Hepatoma Hepatocellular Carcinoma - + TI TI Hepatocellular Carcinoma 
14. 5720/11 71487 45 M ? Hepatoma Metastatic 
Adenocarcinomatous 
Deposits 
TI TI + - Metastatic 
Adenocarcinomatous 
Deposits 
15. 5855/11 73612 70 M ? Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
TI TI - + Metastatic 
Adenocarcinomatous 
Deposits 
16. 236/12 3406 67 M ? Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
17. 554/12 5402 48 F Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
TI TI - - Metastatic 
Adenocarcinomatous 
Deposits 
18. 604/12 9727 50 M  Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
19. 688/12 13156 70 M ? Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
20. 755/12 14325 40 M ? Hepatoma Metastatic 
Adenocarcinomatous 
Deposits 
TI TI + - Metastatic 
Adenocarcinomatous 
Deposits 
21. 1005/12 21258 60 M ? Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
22. 1035/12 22217 71 M ? Hepatoma Metastatic 
Adenocarcinomatous 
Deposits 
TI TI + - Metastatic 
Adenocarcinomatous 
Deposits 
23. 1198/12 25289 78 M  Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
24. 1489/12 29315 59 M Secondaries 
Liver 
Hepatocellular Carcinoma - + TI TI Hepatocellular Carcinoma 
25. 1495/12 29360 68 M  Hepatoma Hepatocellular Carcinoma + + TI TI Hepatocellular Carcinoma 
26. 472/12 18903 52 F Secondaries 
Liver 
Metastatic 
Adenocarcinomatous 
Deposits 
TI TI - + Metastatic 
Adenocarcinomatous 
Deposits 
TI – Tissue Insufficient  
ABSTRACT 
        Hepatocellular carcinoma is the fifth most common malignancy in 
the world. Liver is also a common site for metastatic tumours from 
various solid organs. This is a study of 26 cases of liver biopsies received 
in the Department of Pathology, Coimbatore Medical College Hospital, 
Coimbatore over a period  from July 2011 to September 2012. 
Immunohistochemical markers Alpha Fetoprotein and Hep Par 1 were 
used to confirm the diagnosis of hepatocellular carcinoma; Alpha 
Fetoprotein was positive in 11 out of 13 cases of hepatocellular 
carcinoma(84%) and Hep Par 1 was positive in 12  cases(92%). The 
markers Cytokeratin 7 and Cytokeratin 20 were helpful in secondary 
tumours to assess the possible site of primary. No. of cases of CK7 CK 20 
, CK7 CK 20 , CK7 CK20 ,CK7 CK20 were found to be 54%, 23%, 23% 
and 0% respectively. Reticulin stain was also found to be useful in 
difficult cases to differentiate benign lesions of liver from  well-
differentiated hepatocellular carcinoma. 
 
KEYWORDS: Hepatocellular carcinoma, Alpha Fetoprotein, Hep Par 1, 
Cytokeratin 7, Cytokertain 20, Reticulin  
